54. Ketamine with Paul Glue

This week’s episode features Paul Glue, professor of Psychiatry at the Dunedin School of Medicine, University of Otago, New Zealand.With a vast experience in both academia and pharmaceutical industry, Paul Glue's research focuses on clinical and basic science to investigate the pharmacology of drug treatments in psychiatry and the disease mechanisms of neurological and psychiatric disorders. He is also interested in psychopharmacology and the development of novel therapeutics for affective disorders. One of these novel substances that have dominated his career is ketamine for treatment-resistant depression. Tune in to this episode to listen to a fascinating conversation between two great scientists about, well… Drug Science.KetamineIbogaineNational Institute on Alcohol Abuse and AlcoholismMicrodialysisElectroconvulsive therapy (ECT)NMDA glutamate receptorOverexcitement and disinhibition Dynamic Neurotransmitter Interactions in Alcohol Withdrawal by Paul Glue and David Nutt Methamphetamine John KrystalTreatment-resistant depressionKetamine Assisted PsychotherapyMontgomery-Asberg Depression Rating ScaleDouglas PharmaceuticalsPlasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depressionMechanisms of ketamine action as an antidepressant - P Zanos, T D GouldFood and Drug Administration (FDA)Medicines and Healthcare products Regulatory AgencyGood manufacturing practice (GMP)Paroxetine QT interval The Anti-Addiction Drug Ibogaine and the Heart: A Delicate RelationNoribogaineProzacPsychedelics Promote Structural and Functional Neural Plasticity - Ly et al.Serotonin 2a receptor ★ Support this podcast ★